Patents by Inventor Regino Mercado-Lubo

Regino Mercado-Lubo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating disease using T3SS effector protein (SipA)
    Patent number: 10201589
    Abstract: The invention provides compositions and methods for reducing one or more symptoms of disease by administering compositions comprising SipA. The invention's compositions and methods are particularly advantageous in reducing symptoms of diseases that are associated with overexpression of P-gp and/or p53. The invention's compositions and methods are useful in reducing cancer symptom and/or cancer multidrug resistance (MDR). The invention provides a method for reducing one or more symptoms of cancer in a mammalian subject in need thereof, comprising administering to said subject a composition comprising purified SipA. In one embodiment, said SipA is operably conjugated to a nanoparticle. In another embodiment, said cancer comprises cancer cells resistant to at least one cytotoxin.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: February 12, 2019
    Assignee: University of Massachusetts
    Inventors: Beth McCormick, Regino Mercado-Lubo
  • Compositions and Methods for Treating Disease Using Salmonella T3SS Effector Protein (SipA)
    Publication number: 20170035837
    Abstract: The invention provides compositions and methods for reducing one or more symptoms of disease by administering compositions comprising SipA. The invention's compositions and methods are particularly advantageous in reducing symptoms of diseases that are associated with overexpression of P-gp and/or p53. The invention's compositions and methods are useful in reducing cancer symptom and/or cancer multidrug resistance (MDR). The invention provides a method for reducing one or more symptoms of cancer in a mammalian subject in need thereof, comprising administering to said subject a composition comprising purified SipA. In one embodiment, said SipA is operably conjugated to a nanoparticle. In another embodiment, said cancer comprises cancer cells resistant to at least one cytotoxin.
    Type: Application
    Filed: December 11, 2014
    Publication date: February 9, 2017
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: Beth McCormick, Regino Mercado-Lubo